Prevalence and prognostic significance of cardiac autonomic neuropathy in community-based people with type 2 diabetes: the Fremantle Diabetes Study Phase II

Table 7 Most parsimonious Cox models of independent predictors of all-cause death in the FDS2 type 2 diabetes cohort with CAN category defined (n = 830) and valid CARTs variables as continuous variables added and retained if statistically significant (up to n = 1101)

	HR (95% CI)	P-value
CAN category defined and valid CART results
All-cause mortality (n = 827)
Age (increase of 1 year)	1.06 (1.04, 1.08)	< 0.001
Male sex	1.55 (1.12, 2.15)	0.008
Aboriginal descent	8.95 (3.26, 24.6)	< 0.001
Other European background	0.41 (0.19, 0.90)	0.026
Antidepressant therapy	3.40 (1.44, 8.00)	0.005
Angiotensin receptor blocker use	1.38 (1.001, 1.89)	0.049
eGFR < 30 mL/min/1.73m²	3.03 (1.51, 6.06)	0.002
Distal symmetrical polyneuropathy	1.15 (0.96, 1.39)	0.130
Cerebrovascular disease	1.70 (1.04, 2.77)	0.033
HF	2.31 (1.36, 3.93)	0.002
MCR (increase of 1.0)	0.98 (0.97, 0.99)	0.001
Time-varying covariates
Aboriginal descent	0.43 (0.24, 0.76)	0.004
Antidepressant therapy	0.57 (0.38, 0.98)	0.043
Participants of all ages and valid CART results
All-cause mortality (n = 1091)
Age (increase of 1 year)	1.02 (0.998, 1.05)	0.070
Male sex	1.45 (1.13, 1.87)	0.004
Aboriginal descent	2.61 (1.58, 4.31)	< 0.001
Antidepressant therapy	1.47 (1.08, 2.01)	0.016
Ln(uACR)^a	1.10 (1.004, 1.21)	0.042
eGFR < 30 mL/min/1.73m²	3.20 (1.88, 5.44)	< 0.001
Distal symmetrical polyneuropathy	1.31 (1.09, 1.57)	0.003
Peripheral arterial disease	1.42 (1.09, 1.85)	0.010
HF	1.67 (1.11, 2.50)	0.014
MCR (increase of 1.0)	0.99 (0.98, 0.998)	0.021
Time-varying covariates
Age (increase of 1 year)	1.03 (1.02, 1.05)	< 0.001

Hazard ratios (HR) and 95% confidence intervals (95% CI) are shown
^aA 2.72-fold increase in urinary albumin:creatinine ratio corresponds to an increased risk of 1 in ln (urinary albumin:creatinine)

ISSN: 1475-2840